NCBC 2021 References and Information

CMR Molecular Imaging invites you to visit its exhibit at Booth #105. The LumaGEM® Molecular Breast Imaging (MBI) system will be demonstrated.

MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice. Dibble et al. AJR 2020; 215:277–284

When visiting the exhibit you will be able to chat with company representatives and obtain information about CMR Molecular Imaging products and services.

How Low Dose Functional MBI Works

Technologist/Physician Perspective

Hear from 2 clinical experts on the impact of implementing MBI into their breast practice

Robert Shermis, MD, Director of Breast Care, ProMedica, Toldeo, Ohio
Dawn Merriman, BS, CNMT, Chief Imaging Technologist, ProMedica Breast Care, Toledo, Ohio

Low Dose Molecular Breast Imaging (MBI) LumaGEM system overview

See how the latest MBI technology can aid in supplemental screening, pre-surgical planning and post-operative surveillance when integrated into a multidisciplinary care approach.

Rochelle Keen, CMR Molecular Imaging Consultant

MBI Future Developments – Ultra Low Dose ClearMBI™

We’ll show you how ClearMBI™ will allow for a dose comparable to mammography.

Rochelle Keen, CMR Molecular Imaging Consultant


Ultra low dose imaging O’Connor EUSOBI poster 2019
250% ICDR Rhodes et al. AJR 2015
2x estimated net deaths averted Brown and Covington Radiology: Imaging Cancer 2019

Solo II

3D PET Images
Monitor Neoadjuvant Chemotherapy Nelson et al. ASBrS Poster #255630
90% Sensitivity & Specificity Schilling et al.Applied Radiology 2008